Publications by authors named "Dhruv Chopra"
Article Synopsis
- The study analyzed first-line treatments for advanced non-small cell lung cancer (aNSCLC), focusing on chemotherapy (CT), immunotherapy (IO), and chemoimmunotherapy (IO+CT) costs from 2017 to 2019.
- Utilization of CT significantly decreased while the use of IO+CT rose during the same period, indicating a shift in treatment preferences.
- Patients receiving IO+CT experienced the highest monthly healthcare costs, while those treated with IO had lower costs compared to CT alone, primarily due to differences in drug expenses.
